Unveiling sarcopenia prevalence in post-cancer patients: Integrating functional and morphological assessments for accurate diagnosis
Authors' conclusion
Sarcopenia is highly prevalent in post-cancer patients including younger individuals and those in long-term remission.
Study context
- Population
- Post-cancer patients (age 53.8±11.0 years; Body mass index (BMI) 27.8±6.4 kg/m²); 55 with solid tumors (41 metastatic)68 females
- Participants
- 98 patients
- Exposure
- Sarcopenia vs Without sarcopenia
- Sarcopenian = 27
- Outcome
- Prevalence of sarcopenia (EWGSOP2 criteria)
Methodological detailsstandardized muscle assessment
- Standardized muscle assessment
Main finding
As reported in the abstract
Sarcopenia prevalence (EWGSOP2)
Sarcopenia
27.6%
27
Observational data: associations, not effects.
Further findings
Age, sarcopenia vs without
P = 0.07
BMI, sarcopenia vs without
P < 0.0001
Remission and time after treatment
- Patients with sarcopenia more frequently in remission and long after treatment
Sarcopenia detected by SARC-F screening
- Only 5 patients detected (poor sensitivity)
Muscle measures, whole cohort
- SARC-F score (mean±SD)
- 1.5±1.6
- Grip strength (mean±SD), kg
- 27.3±11.7
- Appendicular lean mass (ALM) index (mean±SD), kg/m²
- 6.4±1.4
- Post-treatment duration (mean±SD), months
- 20.3±21.75
Original publication
Unveiling sarcopenia prevalence in post-cancer patients: Integrating functional and morphological assessments for accurate diagnosis. Joint Bone Spine. Published 22 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →